DARZALEX Faspro daratumumab and hyaluronidase-fihj Updated Nov 8
DARZALEX Faspro is an already-approved, commercially mature product with no upcoming binary catalyst for Halozyme. The next stock-moving events for Halozyme are quarterly royalty reports and the Merck Keytruda Qlex patent litigation outcome. Investors should watch J&J's quarterly daratumumab sales figures and Halozyme's Q4 2026 earnings for royalty growth trajectory.
- DARZALEX Faspro generated $4.239 billion in global net sales in Q3 2026 alone, a massive and growing revenue stream that generates substantial ENHANZE royalties for Halozyme.
- Halozyme's Q3 2026 ENHANZE royalty revenue jumped 44% YoY to a record $341 million, with DARZALEX Faspro being a major contributor.
- Multiple recent FDA approvals (smoldering myeloma Nov 2025, NDMM quadruplet Jan 2026, TECVAYLI combo Mar 2026) continue to expand the addressable market.
- DARZALEX Faspro is a mature marketed product; no binary catalysts remain for Halozyme shareholders tied to this drug.
- Halozyme's ENHANZE royalty stream depends on partner product sales, which could face pricing pressure or competition from oral/next-gen therapies.
- The recent 15.7% stock drop (Nov 6) despite a Q3 beat reflects concerns about marginal guidance raise and a Leerink downgrade to Market Perform.